🚀 VC round data is live in beta, check it out!
Hypera Valuation Multiples
Discover revenue and EBITDA valuation multiples for Hypera and similar public comparables like Sunshine Lake Pharma, Dyne Therapeutics, BB Biotech, Liquidia and more.
Hypera Overview
About Hypera
Hypera SA is a specialty and generic drug manufacturing company. The company has a focus on the pharmaceutical segments of the Brazilian market, along with a presence in nonprescription drugs and branded generics. Hypermarcas also possesses a share of generic medicines and prescription products. The company also has a wide sales and distribution structure. The Company's operating segments are Consumer Health, Branded Prescription, Similars e Generics, Skincare and the Non-Retail Market.
Founded
2001
HQ
Employees
10.5K
Website
Sectors
Financials (LTM)
EV
$5B
Hypera Financials
Hypera reported last 12-month revenue of $2B and EBITDA of $461M.
In the same LTM period, Hypera generated $938M in gross profit, $461M in EBITDA, and $269M in net income.
Revenue (LTM)
Hypera P&L
In the most recent fiscal year, Hypera reported revenue of $2B and EBITDA of $452M.
Hypera expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $2B | XXX | $2B | XXX | XXX | XXX |
| Gross Profit | $938M | XXX | $908M | XXX | XXX | XXX |
| Gross Margin | 59% | XXX | 59% | XXX | XXX | XXX |
| EBITDA | $461M | XXX | $452M | XXX | XXX | XXX |
| EBITDA Margin | 29% | XXX | 29% | XXX | XXX | XXX |
| EBIT Margin | 25% | XXX | 23% | XXX | XXX | XXX |
| Net Profit | $269M | XXX | $239M | XXX | XXX | XXX |
| Net Margin | 17% | XXX | 16% | XXX | XXX | XXX |
| Net Debt | — | — | $2B | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Hypera Stock Performance
Hypera has current market cap of $3B, and enterprise value of $5B.
Market Cap Evolution
Hypera's stock price is $4.68.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $5B | $3B | -0.6% | XXX | XXX | XXX | $0.34 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialHypera Valuation Multiples
Hypera trades at 3.1x EV/Revenue multiple, and 10.5x EV/EBITDA.
EV / Revenue (LTM)
Hypera Financial Valuation Multiples
As of April 21, 2026, Hypera has market cap of $3B and EV of $5B.
Equity research analysts estimate Hypera's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Hypera has a P/E ratio of 12.3x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $3B | XXX | $3B | XXX | XXX | XXX |
| EV (current) | $5B | XXX | $5B | XXX | XXX | XXX |
| EV/Revenue | 3.1x | XXX | 3.1x | XXX | XXX | XXX |
| EV/EBITDA | 10.5x | XXX | 10.7x | XXX | XXX | XXX |
| EV/EBIT | 12.1x | XXX | 13.9x | XXX | XXX | XXX |
| EV/Gross Profit | 5.1x | XXX | 5.3x | XXX | XXX | XXX |
| P/E | 12.3x | XXX | 13.8x | XXX | XXX | XXX |
| EV/FCF | 27.1x | XXX | 13.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Hypera Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Hypera Margins & Growth Rates
Hypera's revenue in the last 12 month grew by 19%.
Hypera's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.1M for the same period.
Hypera's rule of 40 is 52% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Hypera's rule of X is 80% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Hypera Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 19% | XXX | 19% | XXX | XXX | XXX |
| EBITDA Margin | 29% | XXX | 29% | XXX | XXX | XXX |
| EBITDA Growth | 35% | XXX | 33% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 52% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 80% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 29% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 1% | XXX | XXX | XXX |
| R&D Expenses to Revenue | — | XXX | 2% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 36% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Hypera Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Hypera | XXX | XXX | XXX | XXX | XXX | XXX |
| Sunshine Lake Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Dyne Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| BB Biotech | XXX | XXX | XXX | XXX | XXX | XXX |
| Liquidia | XXX | XXX | XXX | XXX | XXX | XXX |
| Denali Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Hypera M&A Activity
Hypera acquired XXX companies to date.
Last acquisition by Hypera was on XXXXXXXX, XXXXX. Hypera acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Hypera
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialHypera Investment Activity
Hypera invested in XXX companies to date.
Hypera made its latest investment on XXXXXXXX, XXXXX. Hypera invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Hypera
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Hypera
| When was Hypera founded? | Hypera was founded in 2001. |
| Where is Hypera headquartered? | Hypera is headquartered in Brazil. |
| How many employees does Hypera have? | As of today, Hypera has over 10K employees. |
| Is Hypera publicly listed? | Yes, Hypera is a public company listed on B3. |
| What is the stock symbol of Hypera? | Hypera trades under HYPE3 ticker. |
| When did Hypera go public? | Hypera went public in 2008. |
| Who are competitors of Hypera? | Hypera main competitors are Sunshine Lake Pharma, Dyne Therapeutics, BB Biotech, Liquidia. |
| What is the current market cap of Hypera? | Hypera's current market cap is $3B. |
| What is the current revenue of Hypera? | Hypera's last 12 months revenue is $2B. |
| What is the current revenue growth of Hypera? | Hypera revenue growth (NTM/LTM) is 19%. |
| What is the current EV/Revenue multiple of Hypera? | Current revenue multiple of Hypera is 3.1x. |
| Is Hypera profitable? | Yes, Hypera is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Hypera? | Hypera's last 12 months EBITDA is $461M. |
| What is Hypera's EBITDA margin? | Hypera's last 12 months EBITDA margin is 29%. |
| What is the current EV/EBITDA multiple of Hypera? | Current EBITDA multiple of Hypera is 10.5x. |
| What is the current FCF of Hypera? | Hypera's last 12 months FCF is $179M. |
| What is Hypera's FCF margin? | Hypera's last 12 months FCF margin is 11%. |
| What is the current EV/FCF multiple of Hypera? | Current FCF multiple of Hypera is 27.1x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.